Halozyme Therapeutics’ wholly owned subsidiary, Halozyme Hypercon, is being licensed to Oruka Therapeutics to develop a candidate for psoriasis treatment.

The global exclusive collaboration and license agreement licenses the Hypercon technology for use with ORKA-001. Oruka has been developing this candidate to treat psoriasis and other related inflammatory diseases.

Not Just Psoriasis

Additionally, Halozyme and Oruka may expand the collaboration for up to one further target.

Oruka primarily concentrates on developing novel biologics that aim to set a new standard for treatment of chronic skin diseases. The potentially best in class antibodies in its proprietary portfolio, engineered by Paragon Therapeutics, target core mechanisms underlying numerous diseases.

The company wants to give patients the “greatest possible freedom” with dosing as little as once or twice a year.

How Hypercon Interfaces with Oruka

In that sense, Hypercon’s innovations in microparticle technology fit nicely with Oruka’s mission. The technology permits hyperconcentration of drugs and biologics; this reduces injection volume per dose, supporting convenient and more patient-friendly administration.

The company has recently engaged Surf Bio’s polymer-based hyperconcentration technology, which broadens the range of subcutaneous delivery for biologics.

Haloyzme Responds

Dr. Helen Torley, Halozyme’s President and CEO, said this was the company’s second Hypercon collaboration in 2026. It validates “broad applicability and partner interest in this technology,” Torley added.

Oruka Therapeutics CEO Lawrence Klein said the partnership will offer the “best possible medicines” to patients with chronic skin conditions.

“We look forward to applying the full potential of this technology to our product candidates,” Klein said.

Financially, Oruka is making an upfront payment to Halozyme, plus potentially future milestone payments. Halozyme, on the other hand, may receive mid-single-digit royalties on net sales of products developed using Hypercon.